PURPOSE: Hyperglycemia has been associated with poor outcomes in many disease states. This retrospective study assessed the association between hyperglycemia and survival in patients with newly diagnosed glioblastoma multiforme (GBM). PATIENTS AND METHODS; Between 1999 and 2004, before the standard use of temozolomide, 191 patients were accrued onto New Approaches to Brain Tumor Therapy CNS Consortium trials with similar eligibility criteria. Time-weighted mean glucose and mean glucocorticoid dose were calculated for each patient using all values collected regularly in follow-up. The primary outcome was survival. RESULTS: Mean glucose levels ranged between 65 and 459 mg/dL. These were divided into quartiles: quartile one (< 94 mg/dL), quartile two (94 to 109 mg/dL), quartile three (110 to 137 mg/dL), and quartile four (> 137 mg/dL). Median survival times for patients in quartiles one, two, three, and four were 14.5, 11.6, 11.6, and 9.1 months, respectively. The association between higher mean glucose and shorter survival persisted after adjustment for mean daily glucocorticoid dose, age, and baseline Karnofsky performance score (KPS). Compared with patients in the lowest mean glucose quartile, those in quartile two (adjusted hazard ratio [HR], 1.29; 95% CI, 0.85 to 1.96), quartile three (adjusted HR, 1.35; 95% CI, 0.89 to 2.06), and quartile four (adjusted HR, 1.57; 95% CI, 1.02 to 2.40) were at progressively higher risk of dying (P = .041 for trend). CONCLUSION: In these patients with newly diagnosed GBM and good baseline KPS, hyperglycemia was associated with shorter survival, after controlling for glucocorticoid dose and other confounders. The effect of intensive management of glucocorticoid-related hyperglycemia on survival deserves additional study in patients with GBM.
PURPOSE:Hyperglycemia has been associated with poor outcomes in many disease states. This retrospective study assessed the association between hyperglycemia and survival in patients with newly diagnosed glioblastoma multiforme (GBM). PATIENTS AND METHODS; Between 1999 and 2004, before the standard use of temozolomide, 191 patients were accrued onto New Approaches to Brain Tumor Therapy CNS Consortium trials with similar eligibility criteria. Time-weighted mean glucose and mean glucocorticoid dose were calculated for each patient using all values collected regularly in follow-up. The primary outcome was survival. RESULTS: Mean glucose levels ranged between 65 and 459 mg/dL. These were divided into quartiles: quartile one (< 94 mg/dL), quartile two (94 to 109 mg/dL), quartile three (110 to 137 mg/dL), and quartile four (> 137 mg/dL). Median survival times for patients in quartiles one, two, three, and four were 14.5, 11.6, 11.6, and 9.1 months, respectively. The association between higher mean glucose and shorter survival persisted after adjustment for mean daily glucocorticoid dose, age, and baseline Karnofsky performance score (KPS). Compared with patients in the lowest mean glucose quartile, those in quartile two (adjusted hazard ratio [HR], 1.29; 95% CI, 0.85 to 1.96), quartile three (adjusted HR, 1.35; 95% CI, 0.89 to 2.06), and quartile four (adjusted HR, 1.57; 95% CI, 1.02 to 2.40) were at progressively higher risk of dying (P = .041 for trend). CONCLUSION: In these patients with newly diagnosed GBM and good baseline KPS, hyperglycemia was associated with shorter survival, after controlling for glucocorticoid dose and other confounders. The effect of intensive management of glucocorticoid-related hyperglycemia on survival deserves additional study in patients with GBM.
Authors: L M A J Muller; K J Gorter; E Hak; W L Goudzwaard; F G Schellevis; A I M Hoepelman; G E H M Rutten Journal: Clin Infect Dis Date: 2005-06-16 Impact factor: 9.079
Authors: Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Beatrice Malmer; Stefan Lönn; Karin Söderberg; Maria Feychting Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Steven S Coughlin; Eugenia E Calle; Lauren R Teras; Jennifer Petrelli; Michael J Thun Journal: Am J Epidemiol Date: 2004-06-15 Impact factor: 4.897
Authors: John J Laterra; Stuart A Grossman; Kathryn A Carson; Glenn J Lesser; Fred H Hochberg; Mark R Gilbert Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: Mary Ann Weiser; Maria E Cabanillas; Marina Konopleva; Deborah A Thomas; Sherry A Pierce; Carmen P Escalante; Hagop M Kantarjian; Susan M O'Brien Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Kenta Masui; Kazuhiro Tanaka; Shiro Ikegami; Genaro R Villa; Huijun Yang; William H Yong; Timothy F Cloughesy; Kanato Yamagata; Nobutaka Arai; Webster K Cavenee; Paul S Mischel Journal: Proc Natl Acad Sci U S A Date: 2015-07-13 Impact factor: 11.205
Authors: Lola B Chambless; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson Journal: J Neurooncol Date: 2011-08-11 Impact factor: 4.130
Authors: Xiuxing Wang; Kailin Yang; Qi Xie; Qiulian Wu; Stephen C Mack; Yu Shi; Leo J Y Kim; Briana C Prager; William A Flavahan; Xiaojing Liu; Meromit Singer; Christopher G Hubert; Tyler E Miller; Wenchao Zhou; Zhi Huang; Xiaoguang Fang; Aviv Regev; Mario L Suvà; Tae Hyun Hwang; Jason W Locasale; Shideng Bao; Jeremy N Rich Journal: Nat Neurosci Date: 2017-03-27 Impact factor: 24.884